WEGOVY® FLEXTOUCH® 2.4mg (Italian)

WEGOVY® FLEXTOUCH® 2.4mg is the full maintenance dose of semaglutide, a once-weekly GLP-1 receptor agonist used for long-term weight management. After progressing through lower titration doses (0.25–1.7mg), patients reach 2.4mg by week 17, where the medication exerts its maximal appetite-regulating and metabolic effects.

This formulation mimics endogenous GLP-1, a hormone that reduces hunger and increases satiety, helping reduce body weight and improve cardiometabolic outcomes. It is prescribed in combination with reduced calorie intake and increased physical activity for adults with obesity or overweight with weight-related conditions.

After completing dose titration over 16 weeks, patients transition to a once-weekly 2.4mg injection for ongoing weight maintenance. The dose is administered subcutaneously with a single-use prefilled pen, which must be discarded after one injection.

• Injection frequency: Once weekly

• Dosage: 2.4 mg semaglutide in 0.5 mL

• Administration sites: Abdomen, thigh, or upper arm

• Injection device: Disposable FlexTouch® pen

• Missed dose: Administer within 5 days; otherwise skip

• No dose adjustment required for elderly patients

• Initiate maintenance dose at week 17 of treatment

WEGOVY® 2.4mg is indicated for chronic weight management in adults with a BMI ≥30 kg/m², or ≥27 kg/m² if they also present with at least one weight-related condition. This includes comorbidities like hypertension, type 2 diabetes, or dyslipidemia.

Indications:

• Obesity (BMI ≥30 kg/m²)

• Overweight (BMI ≥27 kg/m²) with weight-related comorbidities

• Should be used with dietary and physical activity interventions

Contraindications:

• Hypersensitivity to semaglutide or excipients

• Pregnancy or breastfeeding

• Personal/family history of medullary thyroid carcinoma

• Diagnosis of MEN 2

Side Effects:

• Very common (≥10%): Nausea, vomiting, diarrhea, constipation

• Common (1–10%): Headache, dizziness, fatigue, reflux

• Less common/rare: Gallstones, pancreatitis, renal impairment

• Reports of suicidal ideation in post-market surveillance

Each pen delivers 2.4 mg of semaglutide in 0.5 mL of clear, colorless solution. The formulation includes several excipients to stabilize and preserve the compound for injection.

• Active ingredient: Semaglutide 2.4 mg per 0.5 mL

• Excipients:

  • Disodium phosphate dihydrate

  • Sodium chloride

  • Hydrochloric acid and sodium hydroxide (pH adjustment)

  • Phenol (preservative)

  • Water for injections

• pH: 7.4 (approximately)

• Free from animal-derived components

The 2.4mg strength is available in single-use, prefilled disposable FlexTouch® pens. Each pen contains a single fixed dose and must be discarded after use.

• 1 prefilled FlexTouch® pen containing 2.4 mg semaglutide in 0.5 mL

• Designed for one-time use only

• Administered using NovoFine® or compatible needles (not included)

• Pen is color-coded and labeled to avoid dosing errors

Side effects are common but typically manageable and dose-dependent, often occurring during the titration phase. Gastrointestinal events are most frequent, with some risks of more serious but rare adverse events.

• Nausea (≥44%), most common adverse effect

• Diarrhea and vomiting may affect >20% of patients

• Risk of gallbladder disorders including cholelithiasis

• Rare risk: Acute pancreatitis, especially in high-risk patients

• Increased risk of hypoglycemia when used with insulin or sulfonylureas

• Monitor for mood changes or suicidal thoughts

Proper storage is essential to maintain the stability and potency of semaglutide. Once removed from refrigeration, pens have a limited shelf life and must be protected from extreme conditions.

• Refrigerated at 2°C to 8°C before use

• Can be stored at ≤30°C for up to 28 days once removed

• Do not freeze

• Store pen without attached needle

• Protect from direct light and heat

• Discard pen after one injection